The results of the fourth batch of drug collections were announced, which is expected to benefit patients nationwide in May
On the evening of February 8, the National Joint Procurement Office announced the final selection results of the fourth batch of national drug procurement through Shanghai Sunshine Pharmaceutical Purchasing Network.
Prior to February 3, the National Joint Procurement Office had announced the results of the proposed selection.
The centralized procurement involved 45 kinds of drugs and 80 product regulations, covering various treatment fields such as hypertension, diabetes, gastrointestinal diseases, mental diseases, and malignant tumors. According to the news previously announced by the National Medical Insurance Administration, this centralized procurement All purchases were successful, with an average price reduction of 52%.
The National Joint Procurement Office stated in the latest announcement that the specific implementation date will be announced separately, and the National Medical Insurance Bureau revealed on February 3 that it is expected that patients across the country will use the medicines after the price reduction of this centralized procurement in May 2021.
The National Medical Insurance Administration also stated that in accordance with the requirements of normalized and institutionalized drug centralized procurement work, in the future, the scope of centralized drug procurement organized by the state will continue to expand to further ensure clinical drug demand, ensure drug quality and supply, and improve patient benefits.
The list of products supplied in the national centralized drug procurement is as follows:
The Paper Journalist Li Xiaoxiao